<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382160</url>
  </required_header>
  <id_info>
    <org_study_id>PHRI10-DM/AFORA</org_study_id>
    <secondary_id>2010-021449-28</secondary_id>
    <secondary_id>A100898-30</secondary_id>
    <secondary_id>2010-R24</secondary_id>
    <nct_id>NCT01382160</nct_id>
  </id_info>
  <brief_title>Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)</brief_title>
  <acronym>AFORA</acronym>
  <official_title>Serum Concentration of Adalimumab (Humira) as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adalimumab is a fully human monoclonal antibody to tumor necrosis factor-alpha (TNF-α)&#xD;
      approved in rheumatoid arthritis (RA) refractory to disease modifying anti rheumatic drugs&#xD;
      (DMARDs) and for the treatment of severe, active and progressive RA in adults not previously&#xD;
      treated with methotrexate.&#xD;
&#xD;
      However, almost one third of patients have no response and approximately 15% develop&#xD;
      antibodies towards adalimumab (ATA) after a 6 month course of treatment. There is a&#xD;
      relationship between adalimumab concentration and clinical response obtained after 6 month of&#xD;
      treatment. Furthermore adalimumab concentration measured 3 months after initiation seems to&#xD;
      predict the clinical response at 6 months.&#xD;
&#xD;
      There is an important inter individual pharmacokinetic variability of adalimumab. Side&#xD;
      effects may occur at the recommended dose and more than 3 months of treatment are generally&#xD;
      required to estimate the clinical response.&#xD;
&#xD;
      A therapeutic drug monitoring could help clinicians to early adjust the dose to optimize the&#xD;
      response and to avoid dose related side effects. To date there is no definite adalimumab&#xD;
      target concentration predictive of the clinical response to allow such a pharmacologic&#xD;
      monitoring.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis</measure>
    <time_frame>During the 26 weeks of follow up.</time_frame>
    <description>The primary objective is to characterize the concentration-effect relationship of adalimumab in rheumatoid arthritis (RA). To this aim, adalimumab concentration on the one hand and clinical and biological markers of disease activity on the other hand will be measured at baseline, week 4, week 8, week 12 and at week 26. Pharmacodynamic (PD) parameters will be estimated using PK(pharmacokinetic)-PD models in which Emax (maximum effect) and EC50 (concentration at which the effect is 50% of the maximum) will describe adalimumab effect on each markers of response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the relationship between genetic factors, immunogenicity and response to adalimumab in rheumatoid arthritis</measure>
    <time_frame>During the 26 weeks of follow up.</time_frame>
    <description>The secondary endpoints consist on the association study between FCGR3A polymorphisms, transcriptomic analysis (at baseline), presence of antibodies toward adalimumab (ATA) on the one hand and estimited individuals pharmacodynamic parameters on the other hand. Measurements will be carried out at baseline, week 4, week 8, week 12 and at week 26.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg every two weeks, by subcutaneous way</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg every two weeks, by subcutaneous way</description>
    <arm_group_label>adalimumab</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  RA according to the American College of Rheumatology (ACR) 1987 criteria&#xD;
&#xD;
          -  Treatment with Adalimumab has been chosen by the physician / patient&#xD;
&#xD;
          -  Treatment given in accordance to the SPC&#xD;
&#xD;
          -  Stable Disease modifying anti rheumatic drugs (DMARDs) and glucocorticoids 4 weeks&#xD;
             before enrollment and during the study period.&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  more than one previous treatment with anti TNF-alpha&#xD;
&#xD;
          -  Past history of malignancy, AIDS&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Change in DMARDS or glucocorticoid dose 4 weeks before entering the study&#xD;
&#xD;
          -  Active or latent tuberculosis, other active infections&#xD;
&#xD;
          -  Surgery scheduled during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis MULLEMAN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR du Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 2, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>October 1, 2013</last_update_submitted>
  <last_update_submitted_qc>October 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>adalimumab</keyword>
  <keyword>pharmacokinetic-pharmacodynamic relationship</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>Fc gamma receptors polymorphisms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

